Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC increased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,859,232 shares of the company’s stock after acquiring an additional 39,610 shares during the period. Geode Capital Management LLC’s holdings in Neurocrine Biosciences were worth $213,773,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Neurocrine Biosciences in the second quarter valued at about $28,000. Innealta Capital LLC acquired a new position in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $30,000. EdgeRock Capital LLC purchased a new stake in Neurocrine Biosciences in the 2nd quarter valued at approximately $35,000. Blue Trust Inc. grew its holdings in Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after buying an additional 220 shares during the last quarter. Finally, Plato Investment Management Ltd increased its position in Neurocrine Biosciences by 44.1% during the second quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock worth $59,000 after buying an additional 130 shares in the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences Trading Down 0.1 %

Shares of Neurocrine Biosciences stock opened at $126.70 on Monday. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98. The stock has a market cap of $12.83 billion, a price-to-earnings ratio of 33.97 and a beta of 0.34. The company has a fifty day moving average price of $121.75 and a 200 day moving average price of $130.62.

Insider Transactions at Neurocrine Biosciences

In related news, insider Jude Onyia sold 2,331 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. The trade was a 13.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Raymond James restated an “outperform” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a research note on Monday, November 11th. Piper Sandler raised shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $131.00 to $159.00 in a research report on Thursday, August 29th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Finally, Royal Bank of Canada lowered their target price on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research note on Friday, October 4th. Five equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $165.18.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.